HOME >> BIOLOGY >> NEWS
Finding the hole in the defenses of cavity-creating microbes

defenses fell; the cell membrane was no longer able to protect against the acid the bacteria churn out.

"These bacteria should not be able to live in the mouth," says Quivey, "but they adapt to the acidic environment and thrive, thanks to the special defenses they use. Not only that, but the acid they produce harms other bacteria, allowing S. mutans to dominate. We're trying to make the human mouth, the only hospitable environment that S. mutans has ever found, inhospitable."

S. mutans is one of hundreds of types of bacteria in the human mouth. When people eat sugary foods, S. mutans eats the sugars, coats the teeth, excretes acids, and forms a pudding-like goo plaque that consists of bacteria, sugars, and other substances all locked together in a matrix that sticks to teeth. As the crowd of bacteria gathers, it becomes tough for saliva, a healthful substance that bathes the teeth in nutrients and fights cavities, to reach and cleanse the teeth.

"Within an hour after you eat, you can run your tongue over your teeth and feel a sort of film. That's plaque really, a community of bacteria making themselves comfortable for a long-term stay in your mouth. It can really get disgusting in there," says Quivey."

With S. mutans comfortably lodged along our tooth surfaces, the pH in our mouths quickly plummets, becoming 100 to 1,000 times more acidic than normal. Without frequent brushing and flossing, the assault on our teeth results in cavities quickly.

Like S. mutans, other bacteria have the ability to change their cell membranes to cope with harsh conditions. E. coli bacteria happily ensconced in red meat perform a similar trick as they travel through the human digestive system. Another harmful bacterium, Listeria, changes its membrane properties to allow it to live even in the cool temperatures of the refrigerator.

Matching the bacteria's abilities, however, are various human strategies to kill the microbes. Many cu
'"/>

Contact: Tom Rickey
trickey@admin.rochester.edu
585-275-7954
University of Rochester Medical Center
25-Jun-2004


Page: 1 2 3

Related biology news :

1. Findings suggest need for new view of p53 cancer proteins interaction with DNA
2. Findings redefine mechanism of action of RNA helicase enzymes
3. Findings of novel nanoproperties in selenium produced by bacteria open new area of exploration
4. Finding may help eczema sufferers tolerate smallpox vaccine
5. Findings could aid efforts to harness nature for making drugs
6. Findings offer clue to how molecule can both stimulate, suppress cell growth
7. Findings offer further understanding about growth and development in young male gymnasts
8. Findings in frog oocytes may help study of chromosome physiology
9. Finding dirty bombs and other radiation threats
10. Finding life away from Earth will be tough task, says noted paleontologist
11. Finding a Holy Grail: simulated and experimental protein folding compares nicely

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Finding the hole the defenses cavity creating microbes

(Date:2/13/2015)... , Feb. 13, 2015 ACT ... company that aims to transform cancer genomic information ... that the company has raised US$ 8 million in ... Based in Taipei, Taiwan , ... ACTDrug™, ACTOnco™. With the aim to implement next ...
(Date:2/9/2015)... RICHARDSON, Texas , Feb. 9, 2015  Lintec ... novel fabrication methods for carbon nanotube (CNT) macrostructures, including ... Texas at Dallas (UTD). Leveraging the vast ... Tokyo, Japan , Lintec of America ... Richardson, TX , focusing on scaling ...
(Date:2/5/2015)... 2015   Marvin Test Solutions , ... test solutions for military, aerospace, and manufacturing ... TS-323 GENASYS Test Platform to ... is a high-performance PXI-based system designed to ... require performance functional testing. GENASYS features a ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
(Date:2/28/2015)... 2015 Increasing its efforts to resolve the ... first three episodes of The GMO TRUTH podcast on both ... as it continues its mission to discover the truth and ... phase, to “uncover the truth about the GMOs in our ... GMO Truth Podcast is an expansion of the documentary/investigative film-making ...
(Date:2/27/2015)... Calif. , Feb. 27, 2015  Pharmacyclics, ... that longer-term toxicology studies for its newly developed ... or RA, have been completed. The results of ... U.S. Food and Drug Administration. The feedback received ... of the ongoing first-in-human study. Additional preclinical work ...
(Date:2/27/2015)... Halifax, Nova Scotia (PRWEB) February 27, 2015 ... clinical stage vaccine and immunotherapy company, today announced ... approved its application for Fast Track designation and ... DPX-Ebola vaccines, in conjunction with the mutual co-development ... had previously obtained Fast Track designation for the ...
(Date:2/27/2015)... , Feb. 27, 2015  Pfenex Inc. (NYSE ... development of biosimilar therapeutics, today announced that it will ... Marriott Marquis on March 2 nd at 3pm ... on a panel discussing the current state of the ... Biosimilars . For more information on ...
Breaking Biology Technology:The Walk a Mile Project Launches “GMO Truth” Podcast 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3
Cached News: